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esponsibility of Xi’Abstract A highly sensitive, selective, and precise ultra-performance liquid chromatography tandem
mass spectrometry method was developed and validated for simultaneous quantiﬁcation of itraconazole
and hydroxy itraconazole in human plasma by a single liquid–liquid extraction step. The precursor to
product ion transitions of m/z 705.3/392.3, m/z 721.2/408.3 and m/z 708.2/435.4 were used to detect and
quantify itraconazole, hydroxy itraconazole and itraconazole-d3 respectively. The lower limit of
quantitation was found to be 0.500 ng/mL for itraconazole and 1.00 ng/mL for hydroxy itraconazole.
The mean recoveries for itraconazole and hydroxy itraconazole were found to be 100.045% and
100.021%, respectively. This developed method with a chromatographic run time of 2.0 min was
successfully applied to a bioequivalence study of 100 mg itraconazole capsule.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Itraconazole [1–5] (R 51 211), (þ-)-cis-4-[4-[4-[4-[[2-(2,4-dichlor-
ophenyl)-2-(lH-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]sity. Production and hosting by Else
5
430596; fax: þ91 120 2404336.
.com (A. Dwivedi).
an Jiaotong University.methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2(1-methyl-
propyl)-3H-1,2,4-triazol-3-one, is an orally active triazole anti-
fungal agent which demonstrates broad spectrum activity against a
number of fungal species including dermatophytes, Malassesia
furfur, Candida species, Aspergillus species, and Histoplasma
capsulatum var. capsulatum [6]. It is widely used in the treatment
and prophylaxis of a variety of fungal infections, especially
aspergillus species which can cause a hypersensitivity andvier B.V. All rights reserved.
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sis (ABPA) that can result in damage to lung tissues. Itraconazole is a
1:1:1:1 racemic mixture of four diastereomers (two enantiomeric
pairs), each possessing three chiral centers. The structures of
itraconazole and hydroxy itraconazole are shown in Scheme 1.
The mechanism of action for its antifungal activity is believed to
involve efﬁcient inhibition of the fungal-demethylase by itraconazole.
Following oral absorption, it is extensively metabolized including
side chain hydroxylation with CYP3A4 to form hydroxyl itracona-
zole which is the major metabolite. Hydroxy itraconazole is
biologically active and its plasma concentration is two folds higher
than itraconazole at steady state. Itraconazole is extensively metabo-
lized in humans by the liver, yielding over 30 metabolites. It is given
mainly by the oral route (as capsules), but also as an aqueous solution
with a cyclodextrin as a solubilizer. In some countries it is also
available as an injectable solution. The pharmacokinetics of orally
administered itraconazole are of continuing interest, partly because of
its very poor water solubility, which contributes to low, variable
absorption, but also because it is both an inhibitor and substrate of the
CYP3A4 and the P-glycoprotein transporter system. It has a pKa of
3.70 (based on extrapolation of values obtained from methanolic
solutions) and a log(n-octanol/water) partition coefﬁcient of 5.66 at
pH 8.1. Itraconazole is over 99% protein bound and has virtually no
penetration into cerebrospinal ﬂuid. Therefore, it should never be
used to treat meningitis or other central nervous system infections.
The plasma protein binding of itraconazole is 99.8% and that of
hydroxy itraconazole is 99.5%.
Identiﬁcation and quantiﬁcation of itraconazole and hydroxy
itraconazole require a speciﬁc and sensitive method that is suitable
for routine analysis of biological samples. Few methods have been
reported in the literature for quantiﬁcation of itraconazole and its
hydroxy metabolite. The technique used in these includes high
performance liquid chromatography (HPLC) method in human
serum [7–10] and in human plasma [11–16], ﬂourimetric method
in human plasma [17,18] and liquid chromatography tandem mass
spectrometry (LC–MS/MS) method in human plasma. However,
the HPLC methods are less selective and not reliable.
Several papers have been reported for the determination of
itraconazole and hydroxy itraconazole in human plasma by LC–
MS/MS [19–23]. However, their total analysis time per sample and
sample volume requirement often do not suit the requirements forScheme 1 Structures of itraconazole and hydroxy.routine plasma sample analysis of itraconazole. No method was
reported for quantiﬁcation of itraconazole and its hydroxy meta-
bolite in human plasma employing ultra-performance liquid
chromatography/tandem mass spectrometry (UPLC–MS/MS).
The high efﬁciency of sub-2-mm particle columns with UPLC
conditions has made it the ideal partner for mass spectrometry.
Further, this LC system having an ultra-low system volume; a fast,
sensitive, low volume detector; intelligent software; negligible
carry over; and the ability to reliably run at the higher back-
pressures generated by small particles improves results in analyte
resolution, throughput, and sensitivity.
We now report a highly sensitive high throughput UPLC–MS/MS
method for the quantiﬁcation of itraconazole and its metabolite
(hydroxy itraconazole) in human plasma using itraconazole D3 as an
internal standard. The validated method has been successfully used
to analyze samples obtained after the administration of a single dose
of 100 mg itraconazole tablets to healthy volunteers participated in
bioavailability study. The current method includes a very simple,
economical and rapid sample preparation technique as well as
signiﬁcantly shorter analysis run time compared to previously
published methods. Therefore, this easily applicable and low-cost
method can be used for analysis of itraconazole and its metabolite
from human plasma.2. Materials and methods
2.1. Chemicals and reagents
Itraconazole and hydroxy itraconazole standards (purity499.3%)
were obtained from Vivan Life Sciences Pvt. Ltd. (India) and
itraconazole D3 from Clearsynth Labs Pvt. Ltd. (India).
Di-potassium salts of ethylene diamine tetra acetic acid (K2EDTA)
plasma of healthy volunteers were obtained from white cross blood
bank, Mumbai (India). Acetonitrile (HPLC grade) and methanol
were obtained from JT Baker, Germany. A Milli-Q water (Milli-
pore Co., MA, USA) puriﬁcation system was used to obtain
puriﬁed water for the UPLC analysis.
2.2. Instrumentation
Zorbax SB-C18, 50 mm 2.1 mm, 5 mm (Agilent) column was used
for chromatographic separation with a ﬂow rate of 0.400 mL/min.
Chromatography was performed at ambient temperature, with the
mobile phase consisting of acetonitrile and 2 mM ammonium acetate
(pH 3.5 with formic acid) in the ratio of 80:20 (v/v). The mobile
phase was delivered by the ultra-performance liquid chromatography
(UPLC) solvent manager and the samples were injected by a UPLC
sample manager (Waterss Corporation, Milford, MA, USA). Mobile
phase was also used as wash solvent for strong needle wash and weak
needle wash on UPLC system. Milli-Q water was used as seal wash
solution on UPLC system. All the solutions used on UPLC system
were ﬁltered by using 0.22 mm membrane ﬁlters.
Ionization and quantiﬁcation of analytes and IS were performed
on a triple quadrupole mass spectrometer, API-4000 Q-Trap
equipped with Turbo Ion sprays, from MDS SCIEX (Toronto,
Canada) operated in the positive ion mode. Quantitation was done
by using multiple reaction monitoring (MRM) mode to monitor
protonated precursor-product ion transition of m/z 705.3-
392.3, m/z 721.2-408.3 and m/z 708.2-435.4 for itraconazole,
hydroxy itraconazole, and itraconazole D3 respectively. All the
parameters of UPLC and MS were controlled by analyst software
A. Dwivedi et al.318version 1.5.1. The source dependent parameters maintained for
analytes and internal standard were Gas 1 (Nebulizer gas): 35 psi,
Gas 2 (Heater gas): 65 psi, ion spray voltage (ISV): 4000 V, turbo
heater temperature (TEM): 500 1C, entrance potential (EP): 10 V,
collision activation dissociation (CAD): 6 psi, curtain gas (CUR):
30 psi. The compound dependent parameters like declustering
potential (DP), collision energy (CE) and cell exit potential (CXP)
were optimized at 130.00, 51.00 and 11.00 V for itraconazole,
94.00, 52.00 and 11.00 V for hydroxy itraconazole, 80.00, 51.00
and 11.00 V for itraconazole D3 respectively. Optimization of the
triple quadrupole settings of the instrument for the detection of
itraconazole, hydroxy itraconazole, and itraconazole D3 was per-
formed by infusing a 5 ng/mL solution of each drug dissolved in
methanol:water (50:50, v/v) solution at a constant ﬂow rate of 10 mL/
min. Figs. 1 and 2 show a product ion mass spectrum of pure
itraconazole and hydroxy itraconazole.Fig. 1 Product ion spe
Fig. 2 Production spectra o2.3. Preparation of standards and quality control samples
The stock solutions of itraconazole, hydroxy itraconazole and
itraconazole D3 were prepared by dissolving reference standards in
methanol containing 8% formic acid. These stock solutions were
later used to prepare the working solutions of itraconazole,
hydroxy itraconazole and itraconazole D3 in methanol: Milli-Q/
HPLC grade water mixture (50:50, v/v) by appropriate dilution.
Calibration curve standards consisting of eight non-zero concen-
trations were prepared by spiking standards in 0.980 mL of blank
human plasma, each with 0.010 mL working solution of itracona-
zole and hydroxy itraconazole in the concentration range of 0.500–
402.406 ng/mL for itraconazole and 1.000–597.920 ng/mL for
hydroxy itraconazole. Similarly, quality control (QC) standards
were prepared for the lower limit of quantiﬁcation (LLOQ QC),
low quality control (LQC), medium quality control (MQC) andctra of itraconazole.
f hydroxy itraconazole.
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calibration curve range. After bulk spiking, 600 mL of spiked
plasma samples were pipetted out in pre-labeled polypropylene
tubes. The calibration curve standards and QC samples were
logged in ultra-low temperature deep freezer (temperature range:
55 1C to 75 1C) except 24 samples each of LQC and HQC
which were transferred for storage in cell frost deep freezer
(temperature range: 17 1C to 27 1C) for the generation of
long term stability at –2275 1C. These samples were used for
performing the method validation. All the stock solutions were
stored at 2–8 1C for further use.
2.4. Extraction procedure
A set of calibration curve standards and QC samples were
withdrawn from the deep freezer and allowed to thaw at room
temperature in water bath. Plasma samples (500 mL) were pipetted
from the pre-labeled polypropylene tubes into prelabeled 5 mL ria
vials followed by the addition of 50 mL of internal standard
dilution (300 ng/mL). The samples were vortex-mixed for 10 s.
200 mL of 2 M ammonium acetate was then added and samples
were again vortexed. Finally 2 mL methyl tert-butyl ether (TBME)
was added for extraction and samples were vortexed for approxi-
mately 5 min. Once the extraction completed, samples were ﬂash
freezed for 1–2 min and supernatant was decanted off followed by
evaporation to dryness at 40 1C at constant pressure in nitrogen
evaporator. The resulted dried samples were reconstituted with
300 mL of mobile phase, vortexed and transferred into vials for
analysis.
2.5. Validation
The selectivity, sensitivity, linearity, precision, accuracy, recovery,
stabilities and dilution integrity of the method have been validated
according to the US Food and Drug Administration guidance for the
validation of bioanalytical methods [24,25]. Selectivity and speciﬁcity
were determined in six different lots of normal K2EDTA plasma and
four different lots of lipemic K2EDTA and heamolysed K2EDTA
plasma. Three precision and accuracy batches of spiked plasma
calibration curve standard at eight different concentrations levels
ranging from 0.500 ng/mL to 402.406 ng/mL for itraconazole and
1.000 ng/mL to 597.920 ng/mL for hydroxy itraconazole were pre-
pared and analyzed. Weighted 1/(concentration)2 linear regression was
used to construct the itraconazole and hydroxy itraconazole calibration
curves. Spiked QC samples were processed in six replicates at four
concentration levels (0.500, 1.425, 203.534 and 328.280 ng/mL for
itraconazole and 1.000, 2.83, 297.96 and 480.58 ng/mL for hydroxy
itraconazole) for three different analytical batches to evaluate the intra-
and inter-batch assay accuracy and precision. Recovery of both the
analytes were determined in normal K2EDTA plasma at three different
concentrations (1.425, 203.534 and 328.280 ng/mL of itraconazole and
2.830, 297.960 and 480.580 ng/mL of hydroxy itraconazole) by
comparing the analyte peak areas of the extracted QC samples with
those of the non-extracted equivalent QC mixture representing 100%
recovery.
The stability of drug and metabolites in human plasma was studied
by subjecting them into different storage conditions at two different
concentrations (LQC and HQC) levels. For the evaluation of bench top
stability the required number of QC aliquots was kept at room
temperature for 10 h, for evaluating auto-sampler stability the required
number of QC's was processed, reconstituted and kept in autosamplerfor 79 h. After bulk spiking sufﬁcient number of QC's was stored at
65 1C for a period of 306 days and 22 1C for 127 days to access
the long term stability. Freeze/thaw stability was also evaluated after
subjecting for three cycles of freezing and thawing. Dry extract stability
was evaluated after storage of dry extract QC samples at 17 1C to
27 1C in deep freezer for a period of 47 h and wet extract stability
was evaluated after storage of reconstituted QC samples at 2–8 1C in
refrigerator for a period of 24 h. The stabilities were evaluated by
comparing with freshly spiked calibration curve standards and QC
samples in pooled plasma. The analytes were considered stable in
human plasma when a percent change of 715% of the initial
concentration was found. Robustness was analyzed at low and high
pH of buffer solution, at low and high ﬂow rate (0.380 μL/min and
0.420 μL/min) of mobile phase and at low and high column oven
temperature (38 1C and 42 1C). For ruggedness evaluation one
precision and accuracy batch was processed by different analysts and
analyzed by using different columns and different solutions.3. Results and discussion
3.1. Method development
The higher sensitivity of MS/MS detector allowed the development
of a sensitive and robust method for the determination of itracona-
zole and hydroxy itraconazole. Linearity was developed within the
concentration range of 0.500–402.406 ng/mL for itraconazole and
1.000–597.920 ng/mL for hydroxy itraconazole. Results of the back-
calculated concentrations from three calibration curves for itracona-
zole and hydroxy itraconazole using UPLC–MS/MS are tabulated in
Table 1. The table also represents the precision and accuracy for
each standard of the calibration curve. The results obtained were
within the acceptance criteria of 720% of the test concentration at
the LLOQ level and 715% for the standards above LLOQ. Blank
plasma sample clean up was one of the most important point during
the subject sample analysis using UPLC–MS/MS technique. Liquid–
liquid extraction method was investigated with TBME as extraction
solvent and found to be more rugged and robust enabling to enhance
sensitivity and recovery compared to solid phase extraction and
protein precipitation. No endogenous substances were detected,
which signiﬁcantly interfered with the quantiﬁcation of itraconazole
and hydroxy itraconazole. Even though there is an improvement in
cost optimization due to the use of liquid–liquid extraction, still the
aim of the researchers is to reduce the chromatographic run time so
that more number of samples can be analyzed within a day. The
retention times for itraconazole, hydroxy itraconazole and itracona-
zole D3 were found to be within a min. The total chromatography
run time of 2.00 min made it possible to analyze a large number of
samples within a day. Fig. 3 shows representative chromatograms of
itraconazole and hydroxy itraconazole at concentrations of 0.500 ng/
mL and 1.000 ng/mL in plasma along with the IS. A representative
chromatogram of the extracted blank plasma of itraconazole,
hydroxy itraconazole and itraconazole D3 is presented in Fig. 4.
This analytical method was used to analyze plasma samples
containing itraconazole, hydroxy itraconazole and itraconazole D3
from 60 healthy male volunteers after administering single doses of
100 mg itraconazole capsule.
3.2. Precision and accuracy
The inter-batch precision and accuracy were calculated after analyz-
ing three precision and accuracy batches with spiked QC samples.
Table 1 Back calculated concentrations of itraconazole and hydroxy itraconazole (n¼3).
Analyte Standard concentration (ng/mL) Mean (ng/mL) SD CV (%) Nominal (%) Slope Intercept r2
Itraconazole 0.500 0.5047 0.00321 0.64 100.93 0.0716 0.00319 0.9981
1.000 0.9803 0.01286 1.31 98.03
51.495 54.2123 0.38126 0.70 105.28
100.773 104.7237 1.45349 1.39 103.92
181.083 182.6683 0.80404 0.44 100.88
258.335 240.7577 0.80453 0.33 93.20
337.823 343.6347 2.56547 0.75 101.72
402.406 386.5090 4.75955 1.23 96.05
Hydroxy itraconazole 1.00 0.987 0.0451 4.57 98.67 0.0193 0.00202 0.9967
2.00 2.060 0.1700 8.25 103.00
74.80 74.407 6.4174 8.62 99.47
149.60 144.790 1.4839 1.02 96.78
269.06 266.763 4.5265 1.70 99.15
392.08 377.490 8.2378 2.18 96.28
509.70 507.647 2.7153 0.53 99.60
597.92 640.857 14.2873 2.23 107.18
Fig. 3 Representative chromatograms of itraconazole (B1) and hydroxy itraconazole (B2) at concentrations of 0.500 ng/mL and 1.000 ng/mL
with internal standard.
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ing six spiked samples of itraconazole and hydroxy itraconazole at
each QC level (0.500, 1.425, 203.534 and 328.280 ng/mL of
itraconazole and 1.000, 2.830, 297.960 and 480.580 ng/mL of
hydroxy itraconazole). Intra-day and inter-day precision ranged from
1.11% to 3.53% and 1.74% to 4.23% for itraconazole, 2.15% to
7.25% and 2.44% to 7.98% for hydroxy itraconazole while accuracy,
expressed as % nominal was within 90.51–98.48% and 91.41–
98.06% for itraconazole, 97.00–105.65% and 92.22–100.09% for
hydroxy itraconazole respectively, as given in Table 2.3.3. Recovery
The absolute recoveries were evaluated for itraconazole, hydroxy
itraconazole and itraconazole D3 by comparing the peak areas response
of the extracted samples with that of the unextracted stock solutions
at the three QC concentration levels of 1.425, 203.534 and 328.280
ng/mL of itraconazole and 2.830, 297.960 and 480.580 ng/mL of
hydroxy itraconazole. The absolute recovery determination for itraco-
nazole and hydroxy itraconazole was shown to be consistent, precise
and reproducible. The mean recovery for itraconazole, hydroxy
Fig. 4 Representative chromatogram of extracted blank plasma of itraconazole (A1), hydroxy itraconazole (A2) and itraconazole D3.
Table 2 Intraday and interday accuracy of the method for itraconazole and hydroxy itraconazole.
Analyte Level Concentration added
(ng/mL)
Inter-day (n¼6) Intra-day (n¼18)
Mean conc. found
(ng/mL)
Nominal
(%)
CV
(%)
Mean conc. found
(ng/mL)
Nominal
(%)
CV
(%)
Itraconazole LLOQQC 0.500 0.4867 97.33 3.53 0.4903 98.06 4.23
LQC 1.425 1.4033 98.48 1.34 1.394 97.86 1.99
MQC 203.534 198.9537 97.75 3.40 198.8356 97.69 2.89
HQC 328.280 297.1117 90.51 1.11 300.0714 91.41 1.74
Hydroxy
itraconazole
LLOQQC 1.00 0.97 97.00 6.90 0.922 92.22 7.89
LQC 2.83 2.99 105.65 7.25 2.831 100.04 7.98
MQC 297.96 303.173 101.75 7.01 298.219 100.09 4.85
HQC 480.58 483.708 100.65 2.15 480.206 99.92 2.44
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100.021% and 99.495%, respectively.3.4. Stability
The stability of the analytes in human plasma under different
temperatures and times as well as stability of the analytes in stock
solution under different conditions were evaluated. Itraconazole,
hydroxy itraconazole and itraconazole D3 stock solutions were found
stable in 8% formic acid in methanol at 2–8 1C for 9 days. For bench
top stability determination, the required QC aliquots were withdrawn
from deep freezer and kept at room temperature for around 10 h. The
samples were then extracted and analyzed according to the above-
mentioned extraction procedure. No degradation occurred after
leaving the QC aliquots on the bench at room temperature for a
period of 10 h. The required QC aliquots were subjected for three
freeze–thaw cycles to access the freeze–thaw stability. The freeze–
thaw stability was evaluated at the end of the third cycle by analyzing
with the freshly spiked calibration curve (CC) and QC samples in
pooled plasma. The % change between the stability QC samples andcomparison QC samples was observed within acceptance limit. To
determine the autosampler stability, one PA batch was processed and
kept in the autosampler with a set temperature of 5 1C for 79 h and
compared with a freshly prepared calibration curve and QC samples.
No signiﬁcant difference was observed between the concentrations of
freshly spiked QC samples and stability QC samples. For dry extract
stability six sets of LQC and HQC samples were processed and kept
at 17 1C to 27 1C after drying in deep freezer for a period of
47 h and for wet extract stability another six sets of LQC and HQC
samples were processed and after reconstitution stored at 2–8 1C in
refrigerator for a period of 24 h. The dry extract and wet extract
stabilities were evaluated by analyzing the stored QC samples with
the freshly spiked CC and QC samples in pooled plasma. The %
change between the stability QC samples and comparison QC
samples was observed within acceptance limit. The long-term
stability was evaluated for QC samples kept at 22 1C for 127
days and at 65 1C for a period of 306 days at two different
concentrations (LQC and HQC) and was found stable in plasma for
both the analytes for 127 days when stored at 22 1C and for 306
days at 65 1C in polypropylene tubes. The results of all stabilities
are given in Table 3.
Table 3 Stability data of ITR and OH-ITR in processed QC samples for different stability activities in different conditions (n¼6).
Stability
experiment
Analyte Concentration
added (ng/mL)
Mean concentration
found in stability
samples (ng/mL)
Nominal
(%)
CV
(%)
Mean concentration
found in comparison
samples (ng/mL)
Nominal
(%)
CV
(%)
Change
(%)
Bench top
stability (10 h)
ITR 1.425 1.4380 100.91 2.46 1.3918 98.02 2.88 2.95
328.280 317.9462 96.85 1.24 310.5540 94.93 0.96 2.03
OH-ITR 2.83 3.003 106.12 2.64 3.0133 107.24 3.83 1.04
480.58 488.862 101.72 3.07 485.6383 100.84 3.94 0.88
Autosampler
stability (79 h)
ITR 1.425 1.3073 91.74 2.67
328.280 316.5477 96.43 2.65
OH-ITR 2.83 2.7302 96.47 5.76
480.58 498.9805 103.83 7.19
Freeze–thaw
stability
(3-cycles)
ITR 1.425 1.5810 110.95 10.33 1.6070 112.77 11.11 1.62
328.280 297.8808 90.74 0.85 297.9278 90.76 0.99 0.02
OH-ITR 2.83 2.6167 92.46 5.23 2.6683 95.30 4.13 2.98
480.58 421.4617 87.70 9.24 438.7617 91.32 4.73 3.96
Dry extract
stability (47 h)
ITR 1.425 1.5043 105.57 7.38 1.6070 112.77 11.11 6.39
328.280 302.5957 92.18 0.58 297.9278 90.76 0.99 1.56
OH-ITR 2.83 2.703 95.52 4.23 2.668 95.30 4.13 0.24
480.58 452.395 94.14 2.54 438.762 91.32 4.73 3.09
Wet extract
stability (24 h)
ITR 1.425 1.4008 98.30 3.44 1.3918 98.02 2.88 0.29
328.280 313.7125 95.56 0.92 310.5540 94.93 0.96 0.67
OH-ITR 2.83 2.943 104.00 3.59 3.013 107.24 3.83 3.01
480.58 484.422 100.80 5.15 485.638 100.84 3.94 0.04
Long term
stability at
65710 1C
(306 days)
ITR 1.425 1.3792 99.87 3.24 1.4377 104.18 5.35 4.14
328.280 343.0008 103.67 2.71 357.3060 108.09 2.66 4.09
OH-ITR 2.83 2.8380 102.45 4.89 2.8740 103.94 6.26 1.43
480.58 482.0488 97.93 3.07 486.3110 98.97 9.03 1.05
Long term
stability at
2275 1C
(127 days)
ITR 1.425 1.3305 93.37 6.70 1.3197 92.67 6.15 0.75
328.280 305.4362 93.04 4.42 293.9437 89.59 2.97 3.85
OH-ITR 2.83 2.820 99.65 5.13 2.827 99.88 3.92 0.24
480.58 446.580 92.93 2.89 434.613 90.66 1.74 2.49
Table 4 Matrix effect evaluation for itraconazole and
hydroxy itraconazole.
Matrix factor
Analyte LQC HQC
Itraconazole
Mean 1.033 0.973
S.D.7 0.064 0.065
CV (%) 6.20 6.68
Matrix effect (%) 3.30 2.72
Hydroxy itraconazole
Mean 1.119 0.999
S.D.7 0.090 0.026
CV (%) 7.99 2.61
Matrix effect (%) 11.93 0.08
A. Dwivedi et al.3223.5. Matrix effect
Matrix effect was determined by IS normalization matrix factor
[26,27] at LQC and HQC concentration levels by using six
different plasma lots those passed the selectivity criteria. Blank
plasma samples were processed in duplicate from all plasma lots
and after drying these blank plasma samples were reconstituted in
respective prepared neat sample of LQC and HQC concentrations.
The percentage coefﬁcient of variance of both the analytes and
internal standard were within the acceptance range of r15%.
Table 4 shows the data of the results for matrix factor.
3.6. Application of the method
The developed and validated method was successfully applied for
the analysis of plasma samples obtained from the pharmacokinetic
study. The study was conducted as a randomized, open label,
single-dose, two-treatment, two sequence, four-way replicate
crossover in 60 Indian healthy, adult, male, human subjects under
fed condition. Each subject received 100 mg capsule of itracona-
zole of test and reference. Blood samples were collected using
K2EDTA vacutainers at the following times: pre-dose, 1.0, 1.5,
2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 10.0, 12.0,16.0, 24.00, 48.00, 72.00 and 96.0 h after administration. Phar-
macokinetic parameters were calculated from the subjects who had
successfully completed periods I and II of the study. Some of the
Table 5 Pharmacokinetics parameter.
Analyte Drug Statistics Cmax (ng/mL) AUC0-t (ng/mL h) AUC0-inf (ng/mL h)
Itraconazole Test (T) Mean 116.076 1522.932 1613.547
RSD% 62.0924 638.2451 688.1134
Reference (R) Mean 128.940 1662.532 1756.137
RSD% 61.1698 684.1797 719.9309
90% Conﬁdence interval for the ratio of the means T/R (%) 78.540–97.380 82.597–100.300 82.734–100.432
Hydroxy itraconazole Test (T) Mean 159.303 3343.322 3398.416
RSD% 60.6879 1549.1508 1549.0455
Reference (R) Mean 175.738 3660.083 3757.739
RSD% 63.0287 1559.1787 1544.6742
90% Conﬁdence interval for the ratio of the means T/R (%) 81.383–96.583 79.051–99.268 78.372–97.669
Fig. 5 Mean plasma concentration versus time proﬁle of itraconazole
(A) and hydroxy itraconazole (B).
Determination of itraconazole and hydroxy itraconazole in human plasma by UPLC–MS/MS 323main pharmacokinetic parameters are given in Table 5. The mean
plasma concentration versus time proﬁle is shown in Fig. 5.4. Conclusions
A highly sensitive and selective method for the simultaneous
determination of itraconazole and hydroxy itraconazole in human
plasma was developed using UPLC–MS/MS with turbo ion spray in
positive ion mode for the very ﬁrst time with a total analysis run time
of 2.0 min. This developed method was successfully used in a
pharmacokinetic study in which 60 healthy male volunteers were
given a 100 mg capsule of itraconazole in fed condition. The use of
cost effective, time saving and easy to handle liquid–liquid extraction
method made it possible to achieve the sensitivity for both the analytes.By the use of UPLC a shorter chromatographic run time of 2.0 min
was achieved in this method and a large number of subject samples
were easily analyzed on one system in a single day. Only one
analytical column was used to chromatograph about 6000 subject
samples analysis. This validated method is an excellent analytical
option for the simultaneous, rapid quantiﬁcation of itraconazole and
hydroxy itraconazole in human plasma.References
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